Branded Generics Market Size, Industry Trends Report | 2031

Segments - Branded Generics Market by Products (Value-added & Trade Named Generics), Applications (Cardiovascular, Anti-cancer, CNS, and Anti-infective), Distribution Channels (Hospital Pharmacy, Clinics, Pharmacy, and Drug Stores), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031

Author : Raksha Sharma

Fact-checked by : Vineet Pandey

Editor : Vishal Golekar

Report Description

Branded Generics Market Outlook 2031

The Branded Generics Market was USD 327.80 Million in 2022 and is likely to reach USD 688.78 Million, expanding at CAGR of 8.6% during 2023 – 2031. The growth of the market is attributed to the introduction of new medical practices and entry of new market players.

Branded generics are types of generic drugs whose names are assigned by the original drug manufacturing company rather than focusing on the chemical name of the drugs components.

These types of drugs are primarily developed by the original drug developer after the expiration of drugs patent and the branded name of the drugs remained under the control of the original company. However, generic drugs can be available in different brand names but they normally have the same chemical components or active ingredients with the branded drug. Various extrinsic dynamics and internal relating to marketing, manufacturing, and licensing characterize the pharmaceutical industry, which presents a key aspect for the market expansion.

Branded drugs refers to patented drugs, which is the result of pharmaceutical company filing for a patent when they discover new drug. Branded generics are versions of products sold by manufacturers that build brand for their generic segments. These generics drugs are also referred to as value-added generics and are different from commodity generics of pharmaceutical products. These drugs are mainly used as a substitute to innovative products when the patent expires.

Branded Generics Market Trends, Drivers, Restraints, and Opportunities

Large development of pharmaceutical products and increasing cases of patent drugs for several diseases are expected to boost the market growth in the coming years.
Favorable marketing authorization procedures for pharmaceutical products and entry of several new players in the market present key aspects for the market growth.
New clinical practices, changing medical practices, and large profit margin are some other main factors which are further projected to accelerate the market development.
Advancement of innovative pharmaceutical technology and massive R&D activities are key factors, which are expected to offer lucrative opportunities for the market expansion in the near future.
Wide availability of commodity generic products is a key challenge that can restrain the market expansion.

Scope of Branded Generics Market Report

The report on the global branded generics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes	Details
Report Title	Branded Generics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year	2022
Historic Data	2016–2021
Forecast Period	2023–2031
Segmentation	Products (Value-added & Trade Named Generics), Applications (Cardiovascular, Anti-cancer, CNS, and Anti-infective), Distribution Channels (Hospital Pharmacy, Clinics, Pharmacy, and Drug Stores)
Regional Scope	Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage	Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report	Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd.

Branded Generics Market Segment Insights

Value-added & trade named generics segment is expected to grow at a rapid pace

Based on products, the global branded generics market consists of value-added & trade named generics. The value-added & trade named generics segment accounted for a key share of the market in 2020 and is expected to grow at a rapid pace due to large number of pharmaceutical products and increasing competition for advancement of highly effective generic drugs.

Cardiovascular segment is projected to expand at a considerable CAGR

On the basis of applications, the market is divided into cardiovascular, anti-cancer, CNS, and anti-infective. The cardiovascular (CVS) segment is projected to expand at a considerable CAGR during the forecast period due to rising cases of the expiry of CVS drugs patents and increasing demand for effective treatment of heart-related diseases. Meanwhile, the CNS segment is anticipated to expand at substantial growth during the forecast period owing to growth of patent expiry of several key antipsychotics and antidepressants.

Hospital pharmacy segment is expected to expand at a robust growth rate

Based on distribution channels, the global branded generics market is divided into hospital pharmacy, clinics, pharmacy, and drug stores. The hospital pharmacy segment is expected to expand at a robust growth rate during the projected period due to wide availability of innovative pharmaceutical products in hospital pharmacies. On the other hand, the clinics segment is anticipated to expand at a rapid pace during the forecast period due to increasing number of patients visit in clinics due to easy accessibility and low cost.

Branded Generics Market Distribution Channels

North America is anticipated to constitute a key market share

In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the targeted period due to the increasing demand for cost-effective medicines and early adoption of advanced methods for drug discovery in the region. The market of Asia Pacific, however, is anticipated to exhibit a healthy growth rate during the forecast period owing to increasing healthcare infrastructure and government funding in the region.

Segments

The global branded generics market has been segmented on the basis of

Products

Value-added & Trade Named Generics

Applications

Cardiovascular
Anti-cancer
CNS
Anti-infective

Distribution Channels

Hospital Pharmacy
Clinics
Pharmacy
Drug Stores

Regions

Asia Pacific
North America
Latin America
Europe
Middle East & Africa

Key Players

Bausch Health
Mylan N.V.
Cadila Healthcare
Hospira Inc.
Dr. Reddy’s Laboratories Ltd.
Apotex Inc.
Bausch Health
Cadila Healthcare
Sandoz Private Limited
GlaxoSmithKline Pharmaceuticals Limited
AstraZeneca plc.
Par Pharmaceutical Companies, Inc.
Lupin Pharmaceuticals, Inc.
Sanofi
Teva Pharmaceutical Industries Ltd.

Competitive Landscape

Key players competing in the global branded generics market are Bausch Health; Mylan N.V.; Cadila Healthcare; Hospira Inc.; Dr. Reddy’s Laboratories Ltd.; Apotex Inc.; Bausch Health; Cadila Healthcare; Sandoz Private Limited; GlaxoSmithKline Pharmaceuticals Limited; AstraZeneca plc.; Par Pharmaceutical Companies, Inc.; Lupin Pharmaceuticals, Inc.; Sanofi; and Teva Pharmaceutical Industries Ltd. The main market players are continuously engaged in a range of the market development activities such as mergers, acquisitions, research and developments, investments for innovative products, and collaborations to enhance their market share in the long run.

Branded Generics Market key players

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Branded Generics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Branded Generics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Branded Generics Market - Supply Chain
  4.5. Global Branded Generics Market Forecast
     4.5.1. Branded Generics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Branded Generics Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Branded Generics Market Absolute $ Opportunity
5. Global Branded Generics Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Branded Generics Market Size and Volume Forecast by Applications
     5.3.1. Cardiovascular
     5.3.2. Anti-cancer
     5.3.3. CNS
     5.3.4. Anti-infective
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Branded Generics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Branded Generics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Branded Generics Demand Share Forecast, 2019-2026
7. North America Branded Generics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Branded Generics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Branded Generics Market Size and Volume Forecast by Applications
     7.4.1. Cardiovascular
     7.4.2. Anti-cancer
     7.4.3. CNS
     7.4.4. Anti-infective
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Branded Generics Demand Share Forecast, 2019-2026
8. Latin America Branded Generics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Branded Generics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Branded Generics Market Size and Volume Forecast by Applications
     8.4.1. Cardiovascular
     8.4.2. Anti-cancer
     8.4.3. CNS
     8.4.4. Anti-infective
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Branded Generics Demand Share Forecast, 2019-2026
9. Europe Branded Generics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Branded Generics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Branded Generics Market Size and Volume Forecast by Applications
     9.4.1. Cardiovascular
     9.4.2. Anti-cancer
     9.4.3. CNS
     9.4.4. Anti-infective
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Branded Generics Demand Share Forecast, 2019-2026
10. Asia Pacific Branded Generics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Branded Generics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Branded Generics Market Size and Volume Forecast by Applications
     10.4.1. Cardiovascular
     10.4.2. Anti-cancer
     10.4.3. CNS
     10.4.4. Anti-infective
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Branded Generics Demand Share Forecast, 2019-2026
11. Middle East & Africa Branded Generics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Branded Generics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Branded Generics Market Size and Volume Forecast by Applications
     11.4.1. Cardiovascular
     11.4.2. Anti-cancer
     11.4.3. CNS
     11.4.4. Anti-infective
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Branded Generics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Branded Generics Market: Market Share Analysis
  12.2. Branded Generics Distributors and Customers
  12.3. Branded Generics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Bausch Health
     12.4.2. Mylan N.V.
     12.4.3. Cadila Healthcare
     12.4.4. Hospira Inc.
     12.4.5. Dr. Reddy’s Laboratories Ltd.
     12.4.6. Apotex Inc.
     12.4.7. Bausch Health
     12.4.8. Cadila Healthcar